The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Clinical trial NCT05849246 · TERMINATED
Trial details
- NCT number
- NCT05849246
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-31
- Primary completion
- 2023-11-30
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.